Circ_0014235 Confers Gefitinib Resistance and Malignant Behaviors in Non-small Cell Lung Cancer Resistant to Gefitinib by Governing the MiR-146b-5p/YAP/PD-L1 Pathway

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2021 Dec 17

PMID 34919024

Citations 11

Authors

Rong Niu

Dong Li

Jian Chen

Wentao Zhao

Affiliations

Soon will be listed here.

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as Gefitinib, have been recommended as the first-line treatment reagent for advanced EGFR-mutant non-small cell lung cancer (NSCLC). However, the mechanisms of drug resistance development are not fully determined. This study aimed to explore the role of circular RNA (circ_0014235) in Gefitinib-resistant NSCLC. The expression of circ_0014235, microRNA-146b-5p (miR-146b-5p) and Yes1 associated transcriptional regulator (YAP) mRNA was detected by quantitative real-time PCR (qPCR). Cell viability was detected by CCK-8 assay. Cell proliferation was assessed by colony formation assay and EdU assay. Cell cycle and cell apoptosis were determined by flow cytometry assay. The expression of marker proteins, YAP protein and programmed death ligand 1 (PD-L1) protein was detected by Western blot. The putative relationship between miR-146b-5p and circ_0014235 or YAP was ensured by dual-luciferase reporter assay and RIP assay. Animal models were established to explore the role of circ_0014235 . Circ_0014235 was highly expressed in Gefitinib-resistant NSCLC cells. Circ_0014235 downregulation reduced Gefitinib IC50, inhibited cell proliferation and induced cell apoptosis and cell cycle arrest in Gefitinib-resistant NSCLC cells, while these effects were reversed by the inhibition of miR-146b-5p, a target of circ_0014235. In addition, YAP was a target gene of miR-146b-5p, and circ_0014235 relieved miR-146b-5p-mediated inhibition on YAP by targeting miR-146b-5p. MiR-146b-5p restoration-blocked Gefitinib IC50 and cell malignant behaviors were recovered by YAP overexpression. YAP positively regulated PD-L1 expression, and YAP overexpression contributes to Gefitinib IC50 and cell malignant behaviors by upregulating PD-L1. Circ_0014235 confers Gefitinib resistance and malignant behaviors in Gefitinib-resistant NSCLC by governing the miR-146b-5p/YAP/PD-L1 pathway.

Citing Articles

Circular RNAs in lung cancer: implications for preventing therapeutic resistance.

Liu W, Sun Y, Huo Y, Zhang L, Zhang N, Yang M EBioMedicine. 2024; 107:105309.

PMID: 39191172 PMC: 11445705. DOI: 10.1016/j.ebiom.2024.105309.

Circular RNAs in Cell Cycle Regulation of Cancers.

Thamjamrassri P, Ariyachet C Int J Mol Sci. 2024; 25(11).

PMID: 38892280 PMC: 11173060. DOI: 10.3390/ijms25116094.

The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications.

Ma Y, Wang T, Zhang X, Wang P, Long F Cell Death Dis. 2024; 15(5):312.

PMID: 38697964 PMC: 11066075. DOI: 10.1038/s41419-024-06698-3.

The novel miR-873-5p-YWHAE-PI3K/AKT axis is involved in non-small cell lung cancer progression and chemoresistance by mediating autophagy.

Li Z, Liu J, Wang P, Zhang B, He G, Yang L Funct Integr Genomics. 2024; 24(2):33.

PMID: 38363382 DOI: 10.1007/s10142-024-01295-1.

Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions.

Moeinafshar A, Nouri M, Shokrollahi N, Masrour M, Behnam A, Tehrani Fateh S Cancer Cell Int. 2024; 24(1):26.

PMID: 38200584 PMC: 10782702. DOI: 10.1186/s12935-023-03203-2.

References

Shibata M, Ham K, Hoque M . A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 2018; 143(9):2133-2144. PMC: 6540999. DOI: 10.1002/ijc.31561. View

Masucci G, Cesano A, Eggermont A, Fox B, Wang E, Marincola F . The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med. 2017; 15(1):223. PMC: 5670700. DOI: 10.1186/s12967-017-1325-2. View

Hong S . Hippo pathway as another oncogenic mediator to promote immune evasion by PD-L1 signaling. J Thorac Dis. 2019; 11(Suppl 3):S318-S321. PMC: 6424728. DOI: 10.21037/jtd.2019.01.16. View

Recondo G, Facchinetti F, Olaussen K, Besse B, Friboulet L . Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. Nat Rev Clin Oncol. 2018; 15(11):694-708. DOI: 10.1038/s41571-018-0081-4. View

Huang Y, Dai Y, Wen C, He S, Shi J, Zhao D . circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway. Mol Ther Nucleic Acids. 2020; 21:885-899. PMC: 7452060. DOI: 10.1016/j.omtn.2020.07.027. View

Huang G, Zhu H, Shi Y, Wu W, Cai H, Chen X . cir-ITCH plays an inhibitory role in colorectal cancer by regulating the Wnt/β-catenin pathway. PLoS One. 2015; 10(6):e0131225. PMC: 4482251. DOI: 10.1371/journal.pone.0131225. View

Kobayashi S, Boggon T, Dayaram T, Janne P, Kocher O, Meyerson M . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. DOI: 10.1056/NEJMoa044238. View

Planchard D, Popat S, Kerr K, Novello S, Smit E, Faivre-Finn C . Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv192-iv237. DOI: 10.1093/annonc/mdy275. View

Zhou Y, Zheng X, Xu B, Chen L, Wang Q, Deng H . Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway. Biochem Biophys Res Commun. 2018; 508(2):527-535. DOI: 10.1016/j.bbrc.2018.11.157. View

10.

Garcia P, Rosa L, Vargas S, Weber H, Espinoza J, Suarez F . Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer. Cancers (Basel). 2020; 12(4). PMC: 7226626. DOI: 10.3390/cancers12040778. View

11.

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Chirieac L . Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(4):504-535. DOI: 10.6004/jnccn.2017.0050. View

12.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

13.

Song Y, Sun Y, Lei Y, Yang K, Tang R . YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways. Cancer Med. 2019; 9(1):259-268. PMC: 6943160. DOI: 10.1002/cam4.2668. View

14.

Zhang P, Pei X, Li K, Jin L, Wang F, Wu J . Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Cancer. 2019; 18(1):179. PMC: 6900862. DOI: 10.1186/s12943-019-1111-2. View

15.

Miao J, Hsu P, Yang Y, Xu Z, Dai Y, Wang Y . YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget. 2018; 8(70):114576-114587. PMC: 5777715. DOI: 10.18632/oncotarget.23051. View

16.

Wang Y, Zhang H, Wang J, Li B, Wang X . Circular RNA expression profile of lung squamous cell carcinoma: identification of potential biomarkers and therapeutic targets. Biosci Rep. 2020; 40(4). PMC: 7189478. DOI: 10.1042/BSR20194512. View

17.

Di Timoteo G, Rossi F, Bozzoni I . Circular RNAs in cell differentiation and development. Development. 2020; 147(16). DOI: 10.1242/dev.182725. View

18.

Lee B, Park D, Lee J, Yeo M, Park Y, Lim D . Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun. 2017; 491(2):493-499. DOI: 10.1016/j.bbrc.2017.07.007. View

19.

Li B, Zhu L, Lu C, Wang C, Wang H, Jin H . circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021; 12(1):295. PMC: 7804955. DOI: 10.1038/s41467-020-20527-z. View

20.

Xu X, Tao R, Sun L, Ji X . Exosome-transferred hsa_circ_0014235 promotes DDP chemoresistance and deteriorates the development of non-small cell lung cancer by mediating the miR-520a-5p/CDK4 pathway. Cancer Cell Int. 2020; 20(1):552. PMC: 7672955. DOI: 10.1186/s12935-020-01642-9. View